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bjective: To explore the relations that exist between a1-antitrypsin deﬁciency (AATD) and asthma and to
valuate practices for screening patients with asthma for this genetically determined condition in the
ontext of current guidelines.
ata Sources: English-language articles were selected from a PubMed search using combinations of the
following search terms: alpha1-antitrypsin, screening, and asthma.
Study Selections: Studies to be included in this review were based on the authors’ expert opinions.
Results: Asthma and AATD are 2 distinct conditions yet they can coexist. Although AATD has a variable
symptomatology and some patients may be asymptomatic, many can present with symptoms that are
similar to those of asthma, such as dyspnea, wheezing, cough, and mucus production, which can cause
confusion at diagnosis. A simple genetic test exists for AATD, which is a single-gene disorder, and the
American Thoracic Society and European Respiratory Society guidelines recommend the screening of
patients with asthma who exhibit chronic airﬂow obstruction. Patients with AATD are seen by internal
medicine, family medicine, allergy, and pulmonary clinicians, yet there is a generalized lack of awareness of
testing among all specialties. This leads to a delayed diagnosis for patients with AATD, typically by 8.3 years.
Conclusion: A greater awareness of AATD among clinicians who regularly manage patients with asthma
symptoms could increase diagnosis rates, thus optimizing interventions and management strategies to
improve patient outcomes.
 2013 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.
Open access under CC BY-NC-ND license.Introduction to educate on the need for testing and international guidelines forAlpha1-antitrypsin deﬁciency (AATD), an autosomally inherited
disease resulting in low circulating levels of alpha1-antitrypsin
protein, leads to early-onset chronic obstructive pulmonary disease
(COPD).1 In some patients, extrapulmonary symptoms can occur,
most notably liver disease.2 The vast majority (>90%) of individuals
with AATD remain unaware of their condition.3 Underdiagnosis of
AATD might stem from a misperception of low prevalence, misin-
formation about the usual presentation of a patient, and a misun-
derstanding that asthma and AATD are mutually exclusive disease
entities. Although the etiology and disease mechanisms of asthma
and AATD are distinct, patients with AATD commonly ﬁrst present
with asthma-like symptoms4 and initially receive asthma treatment.
Adding to the confusion, it has been recognized that allergy and
asthma often coexist with AATD.4 Owing to overlapping clinical
features, AATD is often overlooked in the differential diagnosis of
asthma and can bemisdiagnosed as asthma.1 Despite ongoing efforts1025 S 6th Street, PO Box 19248,
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y, Asthma & Immunology. Published bwhom should be tested, most patients who are candidates for
screening, including thosewith chronic asthma, are not tested. It has
been reported that, on average, patientswith AATD endure a delay in
diagnosis of approximately 8 years and must see multiple health
providers before a simple blood test to make the diagnosis is
ordered.5
The purpose of this review is to explore the interactions and
overlap between AATD and asthma. The authors examine the
clinical consequences of AATD and discuss the rationale for
extending AATD screening to patients with asthma based on
currently available evidence. If patients with symptoms of asthma
are targeted for AATD screening, research suggests that the disease
might be detected sooner and disease-speciﬁc interventions could
be implemented.Body
Pathophysiology of Respiratory Disease in AATD
Alpha1-antitrypsin (AAT) is a 52-kDa glycoprotein isolated in the
1960s from the alpha1-globulin fraction of blood that was
demonstrated to inhibit trypsin.6 As a member of the serine
protease inhibitor (SERPIN) family of proteins, it inhibits differenty Elsevier Inc. Open access under CC BY-NC-ND license.
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primarily produced and secreted by hepatocytes and is locally
secreted by epithelial cells, alveolar macrophages, and neu-
trophils.7e9 The protein circulates to the lungs through the blood-
stream, where its principal activity is to protect the lungs from
damage induced by the protease enzyme neutrophil elastase (NE).
As part of the normal physiologic response to infection and
inﬂammation, NE degrades components of the extracellular matrix
in the clearance of damaged tissue10 and may have other antibac-
terial11 and proinﬂammatory12 effects. In healthy individuals, AAT
protects the alveoli from the proteolytic effects of NE by main-
taining a balanced milieu between anti- and proinﬂammatory
proteins in the lower respiratory tract.13 It also inhibits other
neutrophil proteases, such as protease-3 and cathepsin-G, and
counteracts the cytotoxic effects of neutrophil defensins.14
There are several lines of evidence implicating AAT as a partici-
pant in the immune response.15,16 In addition to NE, AAT is an
acute-phase reactant.3 Upregulation of AAT occurs in response to
infection and tissue injury, to aid in tissue repair, in a mechanism
that is mediated by interleukin-6 and tumor necrosis factor-a. AAT
also inhibits various lymphocyte cytotoxic reactions, including
T-cell, natural killer cell, and antibody-dependent cell-mediated
processes. Moreover, AAT is thought to decrease the ability of
natural killer cells to bind to their target cells.
In the case of AATD, inheritance of deﬁciency alleles,6 such as
proteinase inhibitors (Pi) Z, S,1 or F,17 or a “null” allele1 causes
decreased, severely deﬁcient, or a complete absence of AAT in the
serum, leading to a protease (ie, NE)/antiprotease imbalance.13
Elastin and other extracellular matrix components in the lower
respiratory tract and alveoli are degraded, resulting in emphysema1
with progressive obstruction and lung function loss. In addition to
enzymatic changes, the Z form of the AAT protein forms polymers
in the lung that act as chemoattractants, thereby recruiting more
neutrophils and amplifying tissue destruction.18
When the lung is regularly exposed to inﬂammatory stimuli, it is
particularly vulnerable to excess NE activity.19 Lung damage is
greatly accelerated by smoking20 and recurrent infections, such as
chronic bronchitis and pneumonia, and is signiﬁcantly affected by
asthma, all of which contribute to unchecked inﬂammation and
unopposed NE activity in the AATD state.AATD: A Common Genetic Disease
Alpha1-antitrypsin deﬁciency is one of the most common
hereditary disorders in the world,21 with a higher genetic preva-
lence than cystic ﬁbrosis in whites.1 The AAT gene (HUGO name
Clade A1) spans 12 kb on the long arm of chromosome 14 in the
SERPIN cluster of genes,22 and it is the Pi locus that encodes the AAT
protein. Pi alleles are inherited codominantly, with genes from both
parents contributing to the overall AAT level. More than 100 AAT
alleles are known to exist, and approximately 35 of these alleles
result in decreased or absent plasma AAT.23 Population-based
screening studies have conﬁrmed the high prevalence of AATD
alleles,24,25 although most of these variants are rare.
The common AAT alleles are M, S, and Z, which correlate with
the expressed proteins’ phenotypes and their migration speed on
an electrophoresis gel (M, medium; S, slow; Z, very slow). M is the
most common allele, present in 80% of individuals, and encodes
a normal AAT protein.26 The S and Z alleles result in abnormal
protein with abnormalities in structure and function. In AATD,
protein expression is typically lower than 30% of the normal
concentration. In patients with the PiZZ genotype, which leads to
severe disease, protein expression is in the order of 10% to 15% of
that found in patients with the PiMM genotype.1
Clinical AATD is most commonly caused by the homozygous
inheritance of the Z allele, which is created by an amino acidsubstitution from glutamic acid to lysine at position 342 in the ﬁfth
exon. This amino acid change occurs in the hinge region of the
reactive site loop, which disrupts a salt bridge that stabilizes the
hinge region and the major beta sheet.27 This disruption of the
b sheet allows for the intercalation of a reactive site loop of another
Z-AAT molecule into its opened b sheet, creating the formation of
Z-AAT polymers. The polymerization of abnormal AAT proteins is
thought to be largely responsible for the substantial decrease in
AAT secretion from hepatocytes, owing to its retention in the
endoplasmic reticulum, and more rapid destruction of the
protein.28,29
The postulated protective threshold of serum AAT is 11 mmol/L.1
In patients with the PiSZ and PiZZ phenotypes, the AAT concen-
trations average 8 to 16 mmol/L and 2.5 to 7 mmol/L, respectively,1
and the extent of the deﬁciency is accompanied by a correspond-
ing degree of emphysema. As expected, computed tomograms have
shown amuch higher frequency of emphysema in patients with the
PiZZ phenotype than with the PiSZ phenotype.30 More than 1
million individuals across the globe are thought to have the PiSZ
phenotype, and it is estimated that approximately 180,000 have the
severe deﬁciency phenotype, PiZZ.31Dilemmas in AATD Diagnosis and Overlap with Asthma
Although AATD is one of the most prevalent diseases that can
lead to signiﬁcant morbidity and mortality, AATD continues to be
underdiagnosed in patients presenting with airﬂow obstruction.
Under-recognition of the disease is due in part to misconceptions
about the proﬁle of a “typical” patient with AATD. The usual
description of a patient with AATD as a young person with an
unremarkable smoking history who has end-stage emphysema is
actually an uncommon presentation. In a study that conducted
universal testing of 965 patients with airway obstruction, the
average age of those with the PiZZ genotype was 55.9 9.8 years.32
In another study, the average smoking history of those with ZZ at
the time of diagnosis was 23.2  14.5 pack-years.33
Current international guidelines recommend AATD screening in
all patients with obstructive lung disease, including the Global
Initiative for Chronic Obstructive Lung Disease34 and the World
Health Organization.35 The consensus statement on AATD by the
American Thoracic Society (ATS) and the European Respiratory
Society (ERS) speciﬁcally recommends genetic screening in all
symptomatic adults with emphysema, in patients with asthmawho
have airﬂow obstruction that is incompletely reversible after
aggressive treatment with bronchodilators, and in all individuals
with unexplained liver disease1 (Box 1).
With respect to asthma, there is an absence of any systematic
recommendation for AATD screening in current guidelines on the
prevention and management of asthma,36,37 thus contributing to
lack of recognition of AATD in patients with asthma. Patients with
AATD often have symptoms that overlap those in all obstructive
lung diseases, especially asthma. Coupled with the variable symp-
tomatology that can be seen among different patients with AATD,
diagnosing AATD in the context of asthma can be confusing.
Although some patients are asymptomatic, many present with
asthma-like symptoms,38 including dyspnea (84%), wheezing
(65%), cough without upper respiratory tract infection (42%), and
cough with mucus production (50%).39 Not surprisingly, AATD is
most commonly misdiagnosed as asthma,40 contributing to
a considerable delay in the correct diagnosis. To complicate
matters, AATD is frequently seen in patients with asthma and,
conversely, patients with AATD are susceptible to developing
asthma owing to increased underlying lung inﬂammation,41
leading asthma to coexist with AATD and emphysema. In a study
of patients with poorly controlled asthma, AATD was present in 2%
to 3% of subjects, with 10.5% being carriers of a deﬁciency gene.42
Box 1. ATS/ERS Task Force Recommendations on Which Individuals Should Undergo Diagnostic Testing for AATD (Type A Categorization) and for Whom Discussion of
Testing Is Appropriate (Type B Categorization)1
Type A: Recommendation for Testing
 All adults with symptomatic emphysema, regardless of smoking history
 All adults with symptomatic COPD, regardless of smoking history
 All adults with symptomatic asthma whose airﬂow obstruction is incompletely reversible after bronchodilator therapy
 Asymptomatic patients with persistent obstruction on pulmonary function tests with identiﬁable risk factors (ie, cigarette smoking, occupational exposure)
 Siblings of individuals with AATD
 Individuals with unexplained liver disease and adults with necrotizing panniculitis
Type B: Discussion of Testing
 Adults with bronchiectasis without evidence of etiology
 Adolescents with persistent airﬂow obstruction
 Asymptomatic individuals with persistent airﬂow obstruction and no risk factors
 Adults with positivity for cytoplasmic antineutrophil cytoplasmic antibodies (antiproteinase-3) vasculitis
 Individuals with a family history of COPD or liver disease not known to be attributed to AATD
 Immediate or distant relatives of an individual homozygous for AATD
D. Siri et al. / Ann Allergy Asthma Immunol 111 (2013) 458e464460In 1963, Laurell and Eriksson6 ﬁrst reported on individuals with
AATD who had clinical symptoms suggestive of bronchial asthma
and demonstrated the presence of emphysema. In the National
Heart, Lung, and Blood Institute’s Registry of AAT Deﬁcient Indi-
viduals, which reported the baseline characteristics of more than
1,000 patients, 55% of patients had a signiﬁcant response to
a bronchodilator.43 In addition, 31% of patients carried a diagnosis
of asthma and 23% had allergies affecting the respiratory tract.39
The lung pathology of patients who died during the National
Heart, Lung, and Blood Institute registry presented with airway
disease in the small and large airways characterized by goblet
hyperplasia and mild inﬂammatory processes.44,45
An association between AATD and liver complications came
several years after the ﬁrst description of the disease.2 In children,10%
to 15% of those with the PiZZ genotype develop symptoms of liver
disease,46 with protracted jaundice and elevated liver enzymes being
the most frequent symptoms in infants.1 In adults, liver cirrhosis is
seen less frequently than the pulmonary symptoms of AATD and
mainly in men older than 50 years.20 Another uncommon extrap-
ulmonary symptom of AATD is necrotizing panniculitis, an inﬂam-
matory condition of the skin and subcutaneous tissue.1 Although
COPD and emphysema are the primary symptoms of AATD, these
other features constitute an important distinction from asthma.
In most individuals with severe AATD, asthma is diagnosed after
COPD symptoms have developed. It has been estimated that
physician-diagnosed asthma is present in up to 50% of patients with
AATD, once the symptoms of COPD have developed.4 Asthma also
can occur alone before COPD is diagnosed.40 Whether asthma
precedes or results from AATD, the presence of coexisting asthma
signiﬁcantly affects the course of AATD, because it is associated
with more severe lung disease.47 The prognosis for individuals whoTable 1




Frequency childhood > adulthood
Family history atopic disease (allergic rhinitis, eczema, asthma, foo
Special features obstruction on spirometry is fully reversible
Concomitant allergies 70%
Diagnosis physical examination, PFTs, demonstration of rever
Treatment glucocorticosteroids, leukotriene modiﬁers, b2 agon
Abbreviations:AAT, alpha1-antitrypsin;AATD, alpha1-antitrypsindeﬁciency;COPD, chronic
aEstimated prevalence in the United States.
bhttp://www.aaaai.org/about-the-aaaai/newsroom/asthma-statistics.aspx.have asthma and AATD is poor.47 There is evidence that patients
with AATD who have bronchial hyper-reactivity have poorer
outcomes and a more rapid decrease in lung function,44,48 with
steeper rates of decreased forced expiratory volume in 1 second
(FEV1) compared with subjects who had no hyper-reactivity (64.6
vs 40.2 mL/year).43 When asthma coexists with AATD, it exacer-
bates COPD symptoms and is a risk factor for more severe COPD.47
The therapeutic options and outcomes differ signiﬁcantly
between asthma and AATD, which underscores the importance of
making the correct diagnosis. Distinguishing AATD from asthma
based on presentation and clinical evaluation is not possible.
Baseline pulmonary function tests and asthma scores have been
shown to be no different in patients with poorly controlled asthma
with and without AATD.42 Although a family history of liver and
lung disease may lend support to its presence, diagnosis of AATD
relies exclusively on laboratory assays.49Comparisons between AATD and Asthma
An estimated 24 million people in the United States (approxi-
mately 1 in 12) have asthma (http://www.aaaai.org/about-the-
aaaai/newsroom/asthma-statistics.aspx). Diagnosis is based on
the thoughtful consideration of multiple variables, which may
include presentation of classic symptoms, conﬁrmation of allergy,
demonstration of airway obstruction by spirometry and airway
reactivity using bronchodilators, establishment of airway inﬂam-
mation, and degree of responsiveness to anti-inﬂammatory treat-
ments, such as corticosteroids.36,37 In distinguishing AATD from
asthma, the clinician must assess each of the elements in the
context of the whole patient, particularly one who does not adhere




d allergies) asthma, emphysema, cirrhosis, and other liver disease
obstruction on spirometry is not reversible
22%40
sibility genetic testing, conﬁrmation by phenotype testing
ists, anti-IgE36 as for COPD þ AAT augmentation therapy
obstructivepulmonarydisease; IgE, immunoglobulinE; PFT, pulmonary function test.
Box 2. Common Strategies for Diagnosing AATD3
 AAT leveldserum testing that reports the circulating AAT concentration
B May be increased by illness or inﬂammation
 AAT phenotype
B Performed by isoelectric focusing on electrophoresis gel
- A low a-globulin fraction on serum protein electrophoresis, performed for other reasons in a patient with pulmonary problems, may indicate the need to
screen for AATD
B Differentiates the different a1 proteins produced compared with known variants
- This method cannot detect “null” alleles, because in these cases no AAT protein is produced
 AAT genotypedperformed by polymerase chain reaction; detects common proteinase inhibitor gene alleles (M, S, Z); may determine affected individuals and
carriers of disease regardless of AAT level; and can form the basis of initiating genetic counselling
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difﬁcult-to-manage asthma should be screened for AATD. The key
features of asthma and AATD are presented in Table 1.19,36,40,50
Considerations for diagnosis are reviewed below.
Age of Presentation
Although asthma is a heterogeneous disease that may present at
any age, it often becomes apparent during childhood and occurs
more frequently in youth. In contrast, the clinical manifestations of
AATD are rarely seen before 25 years of age andmore often occur as
hepatic illness when presenting in childhood.1
Personal or Family History and Evidence for Atopy
Given that the majority of asthma (60%e80%) is allergic by deﬁ-
nition, ie, caused by IgE-mediated airway inﬂammation and hyper-
responsiveness to allergens,51 there is usually evidence toward
genetic predisposition or the presence of other allergic phenomena.
The National Heart, Lung, and Blood Institute’s expert panel guide-
lines recommend allergy testing in the diagnosis and management
of persistent asthma.36 Within the workﬂow of managing the adult
patient with asthma, the absence of allergy should prompt the
physician to consider AATD in the differential diagnosis.
Smoking History
In the case of a patient with asthma who smokes, the concom-
itant use of cigarettes may exacerbate pulmonary symptoms and
obscure the fact that another underlying disease exists. Symptom
onset after a relatively short period of tobacco use or a lack of
improvement in symptoms after smoking cessation should lead the
physician to consider screening for AATD.33 Active tobacco use
should not lead the physician to overlook a possible diagnosis of
AATD. Ideally, active and passive tobacco exposure should always
provoke screening for AATD because smokers are a high-risk pop-
ulationwith poorer outcomes. Furthermore, screening can be a tool
with which to educate patients and effect behavior change.52
Physical Examination
Distinguishing a patient with AATD based on physical exami-
nation alone is not possible.49 Patients with severe obstructive lung
diseases can appear completely normal at a physical examination.
Findings from the examination that are discordant with the
patient’s history might lend a clue to expanding the differential
diagnosis. Certainly, any patient with asthmawho has features that
are suggestive of chronic air trapping should be a candidate for
AATD screening.
Spirometry and Other Diagnostic Tests
Spirometry should always be included in the evaluation of
asthma, including responsiveness to bronchodilators. Lack of any or
complete reversibility to normal values after bronchodilation may
indicate components of ﬁxed or irreversible obstructive lung
disease, which should trigger the clinician to think about AATD.
This may include patients with a decreased FEV1 of less than 80%,a ratio of FEV1 to forced vital capacity no higher than 0.7, or even
patients who have a normal FEV1 or a normal ratio of FEV1 to forced
vital capacity but an abnormal forced expiratory ﬂow rate of 25% to
75% that does not improve after bronchodilator administration.53,54
In the annual evaluation of the patient with asthma, progressive
decreases in lung function are also atypical and should incite the
clinician to screen for AATD. Other considerations may include
pulmonary function testing that shows increased total lung
capacity and residual volumes, normal exhaled nitric oxide levels in
the setting of active asthma symptoms, a predominance of
neutrophils rather than eosinophils from bronchial washings or
biopsies, negative methacholine or mannitol challenge results, and/
or evidence of hyperinﬂation on chest radiographs or computed
tomograms.
As mentioned earlier, a secondary complication of AATD can be
liver disease.2,36 In a patient with presumed asthma and a medical
history of elevated liver enzymes or a family history of liver
cirrhosis, it would be prudent to consider testing for AATD.
Resistance to Usual Asthma Treatment
When the patient with asthma shows a lack of improvement
after receiving the usual therapeutic interventions, there can be
several factors involved, including problems with adherence to the
medication regimen, environmental avoidance measures, and
comorbid disease. Any difﬁcult-to-manage asthma case should be
considered for AATD screening. These may be cases of recurrent
exacerbations, a chronic bronchitis picture, steroid dependence,
and “brittle” asthma. In patients with recalcitrant asthma, medi-
cation nonadherence, comorbid disease, and AATD are more
common than corticosteroid resistance, although corticosteroid
insensitivity is more frequently contemplated.36Discussion
AATD Screening
When approaching atypical or challenging asthma cases, the
acute clinicianwill consider whether AATD is present or coexistent.
The recommendations of the ATS/ERS Task Force for AATD provide
guidance on the differential diagnosis and screening of AATD.1 The
only way to screen is by blood tests, as summarized in Box 2.
The AATD testing involves the collection of a few drops of blood
onto a ﬁlter paper. Then, the dried blood is sent to a specialized
laboratory that performs a polymerase chain reaction test to detect
the most common AATD alleles (M, S, or Z). If a positive result is
returned using this method, further tests are initiated to determine
the patient’s AAT serum level and phenotype (by gel electropho-
resis). The full panel of diagnostic tests for AATD involves serum
level quantiﬁcation, phenotyping, and genotyping. For high-
throughput screening, polymerase chain reactionebased methods
are available, whereas DNA sequencing can be used to deﬁne
speciﬁc genotypes, including rare alleles.
Figure 1. Example of an AATD testing algorithm. With this scheme, rare allele variants will not be picked up and further investigation may need to be considered if clinical
suspicion of AATD is high. AAT, alpha1-antitrypsin; AATD, alpha1-antitrypsin deﬁciency; ATS, American Thoracic Society; COPD, chronic obstructive pulmonary disease; ERS,
European Respiratory Society; PCR, polymerase chain reaction; Pi, proteinase inhibitor.
D. Siri et al. / Ann Allergy Asthma Immunol 111 (2013) 458e464462A spectrum of disease exists for AATD and low to normal serum
levels might provide false reassurance. Testing for AAT levels alone
in a patient with pulmonary problems who has frequent lung
exacerbations or infections may result in cases of mild to moderate
AATD being overlooked and for carriers of 1 deﬁciency-related
allele (eg, PiMZ) to be missed. A further limitation of serum
testing alone is that AAT can be elevated when infection, cancer,
thyroid disorders, and other forms of inﬂammation are present and
may be increased by oral contraceptives, pregnancy, and stress.55
Genetic testing, coupled with conﬁrmation of the patient’s
phenotype, is the optimal method of diagnosing AATD.56
Screening patients with COPD for AATD has greater impact than
population screening because it shows amuch higher prevalence of
AATD genotypes.57 Targeted screening of patients with asthmamay
expose a similar situation. Screening rates might be improved
further by involving the wider multidisciplinary team, ie, respira-
tory therapists and pulmonary function technicians, in testing
candidate patients for AATD.58 The participation of allergists or
immunologists, in addition to that of other physicians who evaluate
and manage pulmonary conditions, is an important facet of iden-
tifying patients with AATD. By introducing a testing algorithm into
their clinic’s work stream, such as that shown in Figure 1, it could be
possible to systematically test all patients whose symptoms are
highly suggestive of AATD.Importance of Early AATD Identiﬁcation
The average age of diagnosis for AATD is 45.5  9.5 years, with
30% of patients diagnosed after 50 years of age.5 Directed AATD
testing in patients with moderate and severe asthma may result in
the detection of not onlymore patients but also of younger patients.
Early diagnosis of AATD enables patients and their families to make
lifestyle changes to lower the risk of emphysema, decrease infec-
tion rates, and optimize their long-term clinical outlook.
The most important preventable risk factor for the progression
of lung disease in AATD is cigarette smoking, which is often asso-
ciated with a lower FEV1 and earlier development of COPD.47
Prognosis is poor for patients with the PiZZ phenotype who
smoke because they have signiﬁcantly lower survival rates than
their nonsmoking counterparts and are expected to die up to 20
years sooner.20 Smoking cessation should be persistently advocated
to slow the progression of lung disease. In a study of smokers,
patients who were diagnosed with AATD were more likely to
attempt smoking cessation than their counterparts who did not
have AATD.52 Patients who are aware of their diagnosis and the risk
factors for progressive disease are more willing and are more
successful in quitting smoking.
Patient reluctance to test for AATD can pose a possible barrier.
Studies of other genetic diseases have indicated that patients
Box 3. Take-Home Points
 AATD is highly under-recognized
 A high index of suspicion is needed so that screening for AATD takes place
 Patients with AATD often present with coexisting asthma and/or asthma-like symptoms
 Patients with asthma who have moderate to severe disease, unusual features, frequent exacerbations, features of ﬁxed obstruction on spirometry, or are difﬁcult to
manage should be screened for AATD
 AATD can be conﬁrmed only by blood testing, which is rapid and accessible
 Education and testing for AATD is a tool to prompt smokers to quit their tobacco habit
 Treatment with AAT augmentation therapy in deﬁcient patients is available and may reduce further decreases in lung function
 Early identiﬁcation leads to early intervention, education, and treatment
 Targeted screening of patients with asthma and COPD will increase identiﬁcation of patients with AATD, allow faster diagnosis, and assist in identifying and
preventing disease in family members
When to Consider Screening of Patients with Asthma
 Strong family history of emphysema, death from a respiratory disease, or cirrhosis
 Asthma without evidence of atopy (negative skin and/or blood test result)
 Asthma that has features of chronic bronchitis or emphysema by subjective or objective measurements
 Asthma that does not improve with usual therapy, or “brittle” asthma
 Steroid-dependent asthma or asthma that is unresponsive to steroids
D. Siri et al. / Ann Allergy Asthma Immunol 111 (2013) 458e464 463exhibit anxiety toward undertaking genetic tests1 and have
negative attitudes toward the perceived outlook for their future
health and that of their family members.59 In eliciting partici-
pation in screening, patients should be informed that genetic
testing is important for eliminating or conﬁrming a diagnosis of
AATD and that an earlier diagnosis translates to earlier initiation
of management strategies, which can lead to improved
outcomes, not only for themselves but also for afﬂicted family
members. Diagnosis of a genetic disorder can have a signiﬁcant
psychologic impact on patients by giving them a reason for their
symptoms, leading to effective behavioral changes.1,52 Improved
awareness of AATD and its complications, knowledge of an
existing a support network or counseling, and availability of
replacement therapy might reassure patients and encourage
them to be evaluated.
Patients who are diagnosed with AATD and who have coexisting
lung problems, such as recurrent or chronic infections, should
continue to be aggressivelymanaged, and full allergy testing should
be given to those who have wheezing and asthma symptoms.
Treatments aimed at decreasing bronchial hyper-responsiveness
and inﬂammation may prevent further deterioration in FEV1.40
Vaccination against pneumococci and inﬂuenza signiﬁcantly
lowers exacerbation frequency in patients with AATD.60 Moreover,
yearly assessments of lung function, pulmonary rehabilitation,
screening for hepatic disease, improving nutrition, and the use of
supplemental oxygen are importantmanagement tools.56 Although
adjunctive treatments can temper inﬂammation and offer some
degree of symptomatic relief, they do not address the underlying
genetically determined deﬁciency, which is met by augmentation
therapy with intravenous infusions of exogenous AAT. Clinical
evidence has indicated positive effects on lung physiology with
augmentation therapy,43,50,61 which can stabilize lung function and
slow down further lung destruction.1
Conclusion
Alpha1-antitrypsin deﬁciency is a serious condition with a high
prevalence among other genetic diseases. Although diagnostic
testing is available, this is carried out infrequently during asthma
consultations, even in patients who have symptoms that are highly
suggestive of AATD. Raising awareness of AATD could be achieved
by a change in the clinical practice guidelines that relate to diag-
nosing and managing asthma. Moreover, the availability of epide-
miologic data on the coexistence of asthma and AATD could raise
the proﬁle of this genetic condition among immunologists who
then might consider it as a differential diagnosis in their patients.The ATS/ERS recommendations inform the practitioner of the
importance of distinguishing the “problem” patient with asthma,
considering the differential diagnosis, and offering testing for
AATD, and additional guidance is detailed in the take-home points
that are listed in Box 3. Allergists or immunologists, primary care
physicians, and other respiratory professionals are ideally situated
to apply existing guidelines for AATD screening in obstructive lung
disease to their patients with asthma. As a consequence, increased
detection rates, earlier identiﬁcation of the disease, and improved
initiation of disease management strategies can occur, thereby
making a positive impact on the long-term outcomes for patients
and their families.
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